The Pathfinder (@path1finder) header
The Pathfinder (@path1finder) profile picture

Private biotech investor with a lot of luck - so far. Don't think that anything that I write makes sense (no investment advice!) and do your own DD! Good luck.

Earth
Joined February 2010
Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)Photo by The Pathfinder (@path1finder)
The Pathfinder retweeted
Replying to @JeromeAdamsMD
MAHA = measles are here again
1
17
1,553
The Pathfinder retweeted
$IDYA IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint •Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint •IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC •Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively •IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026
1
4
1
10
4,233
The Pathfinder retweeted
It’s a privilege to be able to share our Atlas Venture 2026 Year In Review. - Capital markets: Biotech is Back… we hope - innovation industry: patient impact - Atlas Venture: doing well by doing good lifescivc.com/2026/11/atlas-…
7
27
5
189
18,999
The Pathfinder retweeted
$PEPG $125M offering priced at $5/share
6
2
22
7,716
$PEPG valuation still undemanding I think. good risk/reward from here.
1
4
884
doesn't matter that it doubled yesterday. if drug succeeds, still a multibagger, if not... well, cannot lose more than 100% ha
1
255
The Pathfinder retweeted
$DCTH obviously a Q3 blowout. I think Q4 guidance is way too conservative given new starts. Love move into ICC (8x to 10x larger than mUm) w/ good historical evidence from IHP & CHEMOSTAT; cRc interim moved to mid 27 (from late 27); Believe CHOPIN add to NCCN still in cards
2
35
1,472
$VIR $VIR came to kick some ass, apparently… a back to de Backer PR: Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
$VIR Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta Editor: strong case to be made that $VIR is best in class/disease vis a vis $GILD, $MIRM - Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment - 100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus (as defined by HDV RNA TND) at Week 48 $xbi
6
1
16
5,407
$LTGO looks interesting here at about USD 500m EV
265
Today, Xeris Biopharma announced financial results and business highlights for the third quarter ended September 30, 2026. To learn more, read the press release at bit.ly/4sH3SrN. $XERS
2
12
927
The Pathfinder retweeted
"They’re orchestrating a wealth transfer. The stock didn’t even trade—they just gapped it down 20% while the market was closed." $INTC
1
3
44
1,756
The Pathfinder retweeted
"I don’t think the reaction is appropriate to the earnings outcome. Most likley are the Democrats trying to crash the market to get more votes." $INTC
3
3
1
42
2,145
Today we announced positive Phase 1 study results for two novel, non-opioid pain candidates targeting Nav1.7 and Kv7 and plans to advance both candidates to Phase 2 proof-of-concept studies. Read the press release: investor.xenon-pharma.com/ne… @IASPpain #WC2026
1
1
3
1,617
$AXSM with pretty heavy correction the last few weeks. added some today.
1
3
648
The Pathfinder retweeted
Really?
In Fort Myers, FL with Oz & the Boss to announce U.S. harvested seafood labeling and $260 million in nursing scholarships.
2
2
17
3,005
The Pathfinder retweeted
$bhvn 8-k refiling in SCA! 🙏 The FDA has informed Biohaven that the company's new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The resubmission included new positive supportive analyses.
3
3
2
38
14,937